20 years of Cure Parkinson's
We’re here for the cure! This year marks 20 years since Cure Parkinson’s was founded by four people living with Parkinson’s who felt that nobody was taking a cure seriously enough and that there was an urgent need for a focused approach to curative research...
Learn more
Combination therapies: a change in approach for Parkinson’s research
As part of our research strategy, Cure Parkinson’s is seeking to progress research involving combination therapies as a potential method for targeting Parkinson’s progression. Currently, clinical trials of potentially disease-modifying therapies for Parkinson’s are largely focussed on testing single drugs, or monotherapies. These drugs often…
The Movers & Shakers are taking over Cure Parkinson’s!
The Parky Petition has hit 100,000 signatures, but we’re not done yet! We’re highlighting the aims of the petition, the successes of the Movers & Shakers’ journey so far, and the incredible supporters helping drive signatures. Since 2024, the Movers & Shakers podcasters Mark Mardell,…
New registry Join Parkinson’s Research aims to boost awareness and accessibility of clinical research studies for Parkinson’s
The Join Parkinson’s Research (JPR) registry is a new online platform where people living with the condition can register to hear about the latest clinical studies. Clinical research studies are vital to improve our understanding of Parkinson’s and help develop new treatments. However, due to…
Improving diversity in Parkinson’s research – The East London Parkinson’s Disease Project
The East London Parkinson’s Disease Project (ELPD) is a study led by Professor Alastair Noyce at Queen Mary University London. This Cure Parkinson’s supported initiative seeks to better understand the experiences of people with Parkinson’s from diverse ethnic backgrounds. Recently, the ELPD team published a…
Cure InSight: Cure Parkinson’s Spring/Summer 2025 Newsletter
Download the latest edition of our biannual newsletter, Cure InSight, and find out more about the newest developments in research, fundraising and advocacy for Cure Parkinson’s. Our latest newsletter explores updates from from the phase 3 trial of ambroxol (ASPro-PD) and shares how we’ve been…